ReviewMedical2026
Nicotine and Cannabis Co-Use are Associated with Higher Symptom Burden than Use of Either Drug Alone in Early Psychosis: Results from a Multisite Study.
Smucny J.; Campbell E.; Pierce K.; Ward H.; Carter C.; Niendam T.; Lesh T. · medRxiv : the preprint server for health sciences · 2026
Research summary
**Background & Methods**
This cross-sectional, multisite study examined 738 individuals with early psychosis (mean age 22 years, 62% male) from the Early Psychosis Intervention Network (EPI-NET) to assess associations between cannabis and/or nicotine use and symptom burden. Mixed effects models with site as a random factor analyzed relationships between substance use patterns (none, nicotine only, cannabis only, or both) and Modified Colorado Symptom Index (MCSI) scores over a 30-day period, controlling for age and sex.
**Key Findings**
• Co-use of cannabis and nicotine was associated with significantly higher total MCSI symptom scores compared to use of either substance alone or neither substance (F = 6.69, p < .001), indicating greater overall symptom burden in individuals with early psychosis who use both drugs.
• Substance use prevalence in the sample showed 59% used neither substance, 17% used nicotine only, 9% used cannabis only, and 16% used both cannabis and nicotine concurrently.
• More frequent use (daily versus less than daily) of cannabis and/or nicotine was associated with higher total MCSI scores, suggesting a dose-response relationship between substance use frequency and psychotic symptom severity.
**Dosage & Administration**
Not reported.
**Safety & Adverse Effects**
Not reported. The study measured symptom burden through MCSI scoring rather than documenting specific adverse effects or safety outcomes.
**Evidence Quality**
This study represents moderate-quality evidence with several limitations. As a cross-sectional design, it cannot establish causality or determine whether co-use increases symptoms or symptomatic individuals preferentially engage in co-use. The sample is predominantly male (62%) and from specialized early psychosis treatment centers, limiting generalizability. The 30-day recall period for substance use may be subject to measurement error. Additionally, the study is published on medRxiv as a preprint, indicating it has not undergone peer review. Strengths include the large multisite sample (n=738), validated symptom assessment (MCSI), and appropriate statistical modeling with site as a random factor. The exploratory frequency analysis provides additional dimensional understanding, though this analysis was not pre-specified. The findings have potential clinical implications for treatment strategies but require confirmation through prospective studies and mechanistic investigations.
Summary generated by DeepWeed from the published abstract. See the original paper for full methods and results.
Journal
medRxiv : the preprint server for health sciences
Ask how this study fits the wider evidence — across 26,000+ papers.
Ask DeepWeed
More recent cannabis research
This page summarises published research for informational purposes only — it isn't medical advice. Always refer to the original publication for full methods, results and limitations.